Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript May 8, 2024 Tarsus Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Tarsus’s First Quarter 2024 Financial Results Conference Call. As a reminder, this […]
Tarsus Pharmaceuticals (TARS) delivered earnings and revenue surprises of 12.17% and 53.97%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The consensus price target hints at a 38.7% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.